11630 SW 97 Street, Miami, Florida 33176, US

Advertising Driven Press Release Distribution

Tag: Glioblastoma

Curative Biotechnology, Inc. Names Marc Drimer, CPA to Board of Directors

Press Release
Appointment of Independent Director and Chairman of Audit Committee Expands Financial Expertise on Board Boca Raton, FL, July 20, 2021 -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development stage biomedical company focused on novel therapies for rare diseases, announced today that Marc Drimer, CPA has joined its Board of Directors as an independent director and Chairman of the Audit Committee. Mr. Drimer has over 35. Read More>>

Glioblastoma Multiforme (GBM) Epidemiology: A comprehensive analysis of the Patient Population, Medical Practices, and Forecasted Epidemiology Till 2030

Press Release
DelveInsight's 'Glioblastoma Multiforme (GBM) Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Glioblastoma Multiforme (GBM) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The epidemiology report gives a thorough understanding of the disease symptoms and causes, as well as the risk factors, diagnosis, pathophysiology associated with the disease, and treatment guidelines for. Read More>>

Curative Biotechnology, Inc. Announces Ticker Symbol Change to “CUBT” on OTC Markets

Press Release
Company Appoints Kapil Bharti, Ph.D., and Dimiter Dimitrov, Ph.D. to Scientific and Clinical Advisory Board Boca Raton, FL / iCrowd Newswire/ April 29, 2021 / Curative Biotechnology, Inc.  (OTC: CUBT) a development-stage biomedical company focused on novel therapies for rare diseases, announced today the Company's trading symbol change from "CTYX" to "CUBT".  As previously announced, the Company had changed its corporate name to Curative Biotechnology, Inc. to better represent its mission to discover and. Read More>>

Connectyx Technologies Holdings Group, Inc. Announces Definitive Agreement with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies

Press Release
Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases, announced today the Company has signed a definitive agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT) to acquire worldwide rights for the development of IMT504, a novel, patented immunotherapy, to treat symptomatic rabies. IMT504 is being developed to treat patients whose disease has progressed beyond the stage where it can. Read More>>

Subscribe to Our Newsletter

For exclusive content regarding the latest trends in the world of Press Release distribution.